Skip to content
Archyde
  • Economy
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • world

Antiviral Agents* / pharmacokinetics

VV116 Pharmacokinetics & Safety in Mild/Moderate Hepatic Impairment – COVID-19 Treatment

February 25, 2026 by Dr. Priya Deshmukh - Senior Editor, Health
VV116 Pharmacokinetics & Safety in Mild/Moderate Hepatic Impairment – COVID-19 Treatment

The ongoing search for effective oral treatments for COVID-19 has yielded promising results for VV116 (Mindvy, JT001), a deuterated oral derivative of remdesivir hydrobromide. A recent Phase 1 study investigated how well the drug is processed by the body – its pharmacokinetics – and its safety profile in individuals with varying degrees of liver function. … Read more

Categories Health Tags Adenosine / analogs & derivatives, Adenosine Monophosphate* / administration & dosage, Adenosine Monophosphate* / adverse effects, Adenosine Monophosphate* / analogs & derivatives, Adenosine Monophosphate* / pharmacokinetics, administration, adult, Aged, Alanine* / administration & dosage, Alanine* / adverse effects, Alanine* / analogs & derivatives, Alanine* / pharmacokinetics, Antiviral Agents* / administration & dosage, Antiviral Agents* / adverse effects, Antiviral Agents* / pharmacokinetics, Area Under Curve, clinical trial, COVID-19 Drug Treatment*, doi:10.1002/cpdd.70037, female, humans, Liver Diseases* / metabolism, male, MEDLINE, Middle Aged, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Oral, Phase I, pmid:41733177, PubMed Abstract, Tong Lu, Xi Tan, young adult, Yuya Wang Leave a comment
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact:
 [email protected]